A non-covalent inhibitor of GTP-bound Ras
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Daraxonrasib

Item No. 41982

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
(1S,2S)-N-[(2R,14S,18S)-1-ethyl-18,19,20,21-tetrahydro-2-[2-[(1S)-1-methoxyethyl]-5-(4-methyl-1-piperazinyl)-3-pyridinyl]-25,25-dimethyl-15,22-dioxo-17H-5,3-([4,2]-endo-thiazolopropano[1,3]-endo-pyridazinomethanoxypropano)-1H-indol-14-yl]-2-methyl-cyclopropanecarboxamide
CAS Number
2765081-21-6
Synonyms
  • RMC-6236
Molecular Formula
C44H58N8O5S
Formula Weight
811.1
Purity
≥98%
Formulation (Request formulation change)
A solid
Solubility(Learn about Variance in Solubility)
DMSO: Sparingly soluble: 1-10 mg/mlDMSO: Sparingly soluble: 1-10 mg/mlEthanol: Sparingly soluble: 1-10 mg/mlEthanol: Sparingly soluble: 1-10 mg/ml
SMILES
O=C([C@H](CCC1)NN1C([C@H](CC2=NC3=CS2)NC([C@H]4C[C@@H]4C)=O)=O)OCC(C)(C)CC5=[C@@]([C@@]6=C([C@H](C)OC)N=CC(N7CCN(C)CC7)=C6)N(CC)C8=C5C=C3C=C8
InChi Code
InChI=1S/C44H58N8O5S/c1-8-51-37-12-11-28-19-31(37)33(40(51)32-20-29(23-45-39(32)27(3)56-7)50-16-14-49(6)15-17-50)22-44(4,5)25-57-43(55)34-10-9-13-52(48-34)42(54)35(21-38-46-36(28)24-58-38)47-41(53)30-18-26(30)2/h11-12,19-20,23-24,26-27,30,34-35,48H,8-10,13-18,21-22,25H2,1-7H3,(H,47,53)/t26-,27-,30-,34-,35-/m0/s1
InChi Key
FVICRBSEYSHKFY-JYQNNKODSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Wet ice in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $99

    Add

    5 mg

    $272

    Add

    10 mg

    $495

    Add

    25 mg

    $743

    Add
    Cayman Chemical
    Visit Our Cancer Resource Center
    Find Tools & Resources to Study the Hallmarks of Cancer
    • Cancer cell signaling & regulation
    • Cancer metabolism
    • Tumor microenvironment
    EXPLORE NOW
    Product Description

    Daraxonrasib is a non-covalent inhibitor of GTP-bound RAS.1 It binds to peptidyl-prolyl cis-trans isomerase A (PPIase A), also known as cyclophilin A (CypA; Kd = 55.3 nM) to form a binary complex that then binds to wild-type K-Ras, K-Ras(G12V), and K-Ras(G12D) (Kds = 131, 364, and 154 nM, respectively). Daraxonrasib forms a trimeric complex with PPIase A and a K-Ras, H-Ras, N-Ras, or mutant Ras variant and disrupts the protein-protein interaction between these Ras variants and the B-RAF Ras-binding domain (IC50s = 28-220 nM). It induces apoptosis in 28 K-Ras(G12X) and five N-Ras(Q61X) mutant cancer cell lines when used at concentrations ranging from 1 to 100 nM. In vivo, Daraxonrasib (25 mg/kg) inhibits intratumoral ERK phosphorylation and reduces tumor volume in Capan-2 and NCI H441 pancreatic ductal adenocarcinoma (PDAC) mouse xenograft models. It also reduces tumor growth in 29 non-small cell lung cancer (NSCLC), 22 PDAC, and 23 colorectal cancer K-Ras(G12X) mutant mouse xenograft models when administered at a dose of 25 mg/kg.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Jiang, J., Jiang, L., Maldonato, B.J., et al. Translational and therapeutic evaluation of RAS-GTP inhibition by RMC-6236 in RAS-driven cancers. Cancer Discov. 14(6), 994-1017 (2024).